Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

BeiGene Forms India Distribution Partnership with Mumbai’s Glenmark

publication date: May 22, 2024

Beijing’s BeiGene announced an agreement to develop and distribute two of its marketed products in India with Glenmark Pharma of Mumbai. Glenmark will be responsible for approval and commercialization of Tislelizumab and Zanubrutinib in India. Tislelizumab is BeiGene’s anti-PD-1 monoclonal antibody approved to treat esophageal squamous cell carcinoma that is also in trials for other cancers. Zanubrutinib is a BTK inhibitor approved to treat hematological malignancies. Financial details of the agreement were not disclosed. More details....

Share this with colleagues:  

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital